Modulation of hippocampal norepinephrine release by cholinergic agonists is altered by AF64A lesion

Brain Research Bulletin

Volumn 42, Issue 2, 1997, Pages 153-160

  Potter, Pamela E ^a   Thorne, Beverly ^a   Gaughan, Christopher ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

AF64A; Cholinergic lesion model; Hippocampal norepinephrine release; McN A 343; Nicotine; Oxotremorine

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; ETHYLCHOLINE MUSTARD AZIRIDINIUM; NORADRENALIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROSTIMULATION; HIPPOCAMPUS; MALE; NEUROCHEMISTRY; NEUROTOXICITY; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

EID: 0030463945     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(96)00115-3     Document Type: Article

References (38)

1. 1. Aubert, I.; Araujo, D. M.; Cecyre, D.; Robitaille, Y.; Gauthier, S.; Quirion, R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J. Neurochem. 58:529-541; 1992.
2. 2. Bartus, R. T.; Dean, R. L.; Beer, B.; Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-417; 1982.
3. 3. Bauer, J.-B.; Zilles, K. Muscarinic desensitization after septal lesions in rat hippocampus: Evidence for the involvement of G-proteins. Neuroscience 47:95-103; 1992.
4. 4. Bourne, H. R. One molecular machine can translate diverse signals. Nature 321:814-816; 1986.
5. 5. Coyle, J. T.; Price, D. L.; Delong, M. R. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 219:1184-1190; 1983.
6. 6. Davies, P.; Verth, A. H. Regional distribution of muscarinic acetylcholine receptor in normal and Alzheimer's-type dementia brains. Brain Res. 138:385-392; 1978.
7. 1 receptors. Brain Res. Bull. 25:311-317; 1990.
8. 8. Fisher, A.; Mantione, C. R.; Abraham, D. J.; Hanin I. Long-term central cholinergic hypofunction induced in mice by ethylcholine aziridinium ion (AF64A) in vivo. J. Pharmacol. Exp. Ther. 222:140-145; 1982.
9. 3H] nicotine binding in human cerebral cortex: Comparison between Alzheimer's disease and the normal. J. Neurochem. 47:1948-1954; 1986.
10. 1 muscarinic receptors in Alzheimer's disease: Implications for the failure of cholinergic replacement therapies. Ann. Neurol. 29:256-262; 1991.
11. 11. Fonnum, F. Rapid radiochemical method for the determination of choline acetyltransferase. J. Neurochem. 24:407-409; 1975.
12. 12. Fowler, C. J.; O'Neill, C.; Garlind, A.; Cowburn, R. F. Alzheimer's disease: Is there a problem beyond recognition? Trends Pharmacol. Sci. 11:183-184; 1990.
13. 2 biochemical and functional characterization. Life Sci. 31:2991-2998; 1982.
14. 14. Jarrard, L. E.; Kant, G. J.; Meyerhoff, J. L.; Levy, A. Behavioral and neurochemical effects of intraventricular AF64A administration in rats. Pharmacol. Biochem. Behav. 21:273-280; 1984.
15. 15. Kellar, K. J.; Whitehouse, P. J.; Martino-Barrows, A. M.; Marcus, K.; Price, D. L. Muscarinic and nicotinic binding sites in Alzheimer's disease cerebral cortex. Brain Res. 435:62-68; 1987.
16. 16. Leventer, S.; McKeag, D.; Clancy, M.; Wulfert, E.; Hanin, I. Intracerebroventricular administration of ethylcholine mustard aziridinium ion (AF64A) reduces release of acetylcholine from rat hippocampal slices. Neuropharmacology 24:453-459; 1985.
17. 17. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275; 1951.
18. 18. Mantione, C. R.; Fisher, A.; Hanin, I. The AF64A-treated mouse: Possible model for central cholinergic hypofunction. Science 213:579-580; 1981.
19. 2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228:1115-1117; 1985.
20. 20. Milusheva, E.; Baranyi, M.; Zelles, T.; Mike, Á.; Vizi, E. S. Release of acetylcholine and noradrenaline from the cholinergic and adrenergic afferents in rat hippocampal CA1, CA3 and dentate gyrus regions. Eur. J. Neurosci. 6:187-192; 1994.
21. 21. Mouton, P. R.; Meyer, E. M.; Dunn, A. J.; Millard, W.; Arendash, G. W. Induction of cortical cholinergic hypofunction and memory retention deficits through intracortical AF64A infusions. Brain Res. 444:104-118; 1988.
22. 22. Nilsson, L.; Adem, A.; Hardy, J.; Winblad, B.; Nordberg, A. Do tetrahydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via presynaptic nicotinic receptors? J. Neural Transm. 70:357-368; 1987.
23. 23. Nordberg, A.; Alafuzoff, I.; Winblad, B. Muscarinic receptor subtypes in hippocampus in Alzheimer's disease and mixed dementia type. Neurosci. Lett. 70:160-164; 1986.
24. 24. Perry, E. K.; Perry, R. H.; Smith, C. J.; Purohit, D.; Bonham, J.; Dick, D. J.; Candy, J. M.; Edwardson, J. A.; Fairbairn, A. Cholinergic receptors in cognitive disorders. Can. J. Neurol. Sci. 13:521-527; 1986.
25. 25. Potter, P. E.; Nitta, S. Alterations in modulation of acetylcholine release following lesion of hippocampal cholinergic neurons with the neurotoxin AF64A. Neuropharmacology 32:519-526; 1993.
26. 26. Potter, P. E.; Hàrsing, L. G., Jr.; Kakucska, I.; Gaàl, G.; Vizi, E. S. Selective impairment of acetylcholine release and content in the central nervous system following intracerebroventricular administration of ethylcholine mustard aziridinium ion (AF64A) in the rat. Neurochem. Int. 8:199-206; 1986.
27. 1 muscarine receptors. J. Pharmacol. Exp. Ther. 248:974-978; 1989.
28. 3H]norepinephrine release is modulated by glycine. Eur. J. Pharmacol. 156:149-155; 1988.
29. 29. Ricny, J.; Collier, B. Effect of 2-(4-phenylpiperidino) cyclohexanol on acetylcholine release and subcellular distribution in rat striatal slices. J. Neurochem. 47:1627-1633; 1986.
30. 3H-(1-[1-(2-thienyl)cyclohexyl]-piperidine) binding in rat hippocampus. Synapse 3:129-135; 1989.
31. 31. Thorne, B.; Potter, P. E. Lesion with the neurotoxin AF64A alters hippocampal cholinergic receptor function. Brain Res. Bull. 38:121-127; 1995.
32. 32. Thorne, B.; Wonnacott, S.; Dunkley, P. R. Isolation of hippocampal synaptosomes on Percoll gradients: Cholinergic markers and ligand binding sites. J. Neurochem. 56:479-484; 1991.
33. 33. Vickroy, T. W.; Watson, M.; Leventer, S. M.; Roeske, W. R.; Hanin, I.; Yamamura, H. I. Regional differences in ethylcholine mustard aziridinium ion (AF64A)-induced deficits in presynaptic cholinergic markers for the rat central nervous system. J. Pharmacol. Exp. Ther. 235:577-582; 1985.
34. 34. Vizi, E. S.; Sershen, H.; Balla, A.; Mike, &Aaucte.; Windisch, K.; Jurányi, ZS.; Lajtha, A. Neurochemical evidence of heterogeneity of presynaptic and somatodendritic nicotinic acetylcholine receptors. Ann. NY Acad. Sci. 757:84-99: 1995.
35. 35. Wall, S. J.; Wolfe, B. B.; Fromer, L. F. Cholinergic deafferentation of dorsal hippocampus by fimbria-fornix lesioning differentially regulates subtypes (m1-m5) of muscarinic receptors. J. Neurochem. 62:1345-1351; 1994.
36. 36. Walsh, T. J.; Tilson, H. A.; DeHaven, D. L.; Mailman, R. B.; Fisher, A.; Hanin, I. AF64A, a cholinergic neurotoxin, selectively depletes acetylcholine in hippocampus and cortex, and produces long term passive avoidance and radial-arm deficits in the rat. Brain Res. 321:91-102; 1984.
37. 37. Wang, H.-Y.; Freidman, E. Receptor-mediated activation of G proteins is reduced in postmortem brains from Alzheimer's disease patients. Neurosci. Lett. 173:37-39; 1994.
38. 38. Yamazaki, N.; Kato, K.; Kurihara, E.; Nagaoka, A. Cholinergic drugs reverse AF64A induced impairment of passive avoidance learning in rats. Psychopharmacology (Berlin) 103:215-222; 1991.